These data strongly suggest that PDE4 inhibitor roflumilast attenuates the development of TAC-induced HF by promoting cardiac mitophagy via SIRT1-mediated PINK1/Parkin pathway. The gene discussed is PDE4A; the disease is persistent truncus arteriosus.